Assessment of cerebrospinal fluid levels of serum amyloid P component in patients with Alzheimer's disease

• Published in: Neuroscience letters 1999-10, Vol.273 (2), p.137-139
• Main Authors: Kimura, M., Asada, T., Uno, M., Machida, N., Kasuya, K., Taniguchi, Y., Fujita, T., Nishiyama, E., Iwamoto, N., Arai, H.
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - psychology; Alzheimer's disease; Amyloid P component; Biological and medical sciences; Cerebrospinal fluid; Cognition; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Dementia - cerebrospinal fluid; Humans; Medical sciences; Mental Status Schedule; Middle Aged; Mini-Mental State Examination; Neurology; Reference Values; Serum Amyloid P-Component - cerebrospinal fluid; Soluble amyloid precursor protein; Tau protein; tau Proteins - cerebrospinal fluid
• ISSN: 0304-3940; 1872-7972
• DOI: 10.1016/S0304-3940(99)00631-X

Serum amyloid P component (SAP) is a normal plasma constituent that is observed both in senile plaque and in neurofibrillary tangle in brains of patients with Alzheimer's disease (AD). In this study, we evaluated the SAP levels in cerebrospinal fluid (CSF) of 72 patients with AD, 11 frontotemporal dementia and nine normal control subjects. There was no significant difference in the SAP levels between the AD group and other groups. However, among AD patients, cognitive function was rated using the Mini-Mental State Examination and was correlated with the SAP level ( R=0.38, P